Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Stemline Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05386108CT.gov Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abemaciclib (this asset) | Stemline Therapeutics, Inc. | P1/2 | CC · 45 |
| Galantamine Hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B |
| Donanemab | Eli Lilly and Company | P3 | B |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | B |
| Fremanezumab | Hospital Clínico Universitario de Valladolid | P4 | B |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | B |
| Levodopa | Merck Sharp & Dohme LLC | P2 | B |
| Tocilizumab | Zhujiang Hospital | P3 | B |
| Physiologic Sodium Chloride Solution | Zhujiang Hospital | P3 | B |
+33 more in the Brain Disorder cohort
Other indications for Abemaciclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 70 |
| Metastatic Neoplasm | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Galantamine HydrobromideJohnson & Johnson Pharmaceutical Research & Development, L.L.C.B
- DonanemabEli Lilly and CompanyB
- Live Combined BifidobacteriumBeijing Friendship HospitalB
- FremanezumabHospital Clínico Universitario de ValladolidB
- Live Combined Bifidobacterium,Lactobacillus And Enterococcus CapsulesBeijing Friendship HospitalB
Citation
Floatz Terminal. Abemaciclib in Brain Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abemaciclib-brain-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →